HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,880,050 | -58.3% | 127,750 | -37.9% | 0.25% | -59.2% |
Q4 2022 | $11,703,192 | +36.6% | 205,680 | -5.1% | 0.61% | +28.1% |
Q3 2022 | $8,570,000 | -4.5% | 216,750 | +6.3% | 0.48% | -0.6% |
Q2 2022 | $8,973,000 | +0.4% | 203,940 | -7.2% | 0.48% | +40.4% |
Q3 2021 | $8,941,000 | -38.0% | 219,787 | -30.8% | 0.34% | -29.5% |
Q2 2021 | $14,431,000 | -19.6% | 317,787 | -26.2% | 0.48% | -24.9% |
Q1 2021 | $17,952,000 | -15.8% | 430,602 | -13.7% | 0.65% | -19.0% |
Q4 2020 | $21,318,000 | +35.5% | 499,142 | -16.6% | 0.80% | +29.5% |
Q3 2020 | $15,732,000 | +4.6% | 598,617 | +6.7% | 0.62% | -5.8% |
Q2 2020 | $15,045,000 | +91.0% | 561,185 | +28.2% | 0.65% | +40.3% |
Q1 2020 | $7,877,000 | +10.3% | 437,870 | +3.4% | 0.47% | +111.8% |
Q2 2018 | $7,141,000 | -15.8% | 423,305 | -2.2% | 0.22% | -18.2% |
Q1 2018 | $8,480,000 | +19.5% | 432,884 | +23.6% | 0.27% | +26.3% |
Q4 2017 | $7,098,000 | +75.4% | 350,355 | +50.4% | 0.21% | +67.7% |
Q3 2017 | $4,046,000 | – | 232,905 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 1,129,551 | $47,091,000 | 6.38% |
First Light Asset Management, LLC | 2,011,350 | $83,853,000 | 5.56% |
TRAN CAPITAL MANAGEMENT, L.P. | 1,353,208 | $56,415,000 | 5.03% |
SNYDER CAPITAL MANAGEMENT L P | 2,920,860 | $121,771,000 | 3.50% |
DOHENY ASSET MANAGEMENT /CA | 120,028 | $5,004,000 | 3.39% |
SILVERARC CAPITAL MANAGEMENT, LLC | 104,945 | $4,375,000 | 2.39% |
Redwood Investments, LLC | 542,764 | $22,628,000 | 1.99% |
Kent Lake Capital LLC | 85,000 | $3,544,000 | 1.44% |
Lisanti Capital Growth, LLC | 263,460 | $10,984,000 | 1.41% |
Bellevue Group AG | 3,011,966 | $125,569,000 | 1.33% |